 |
|
|
| |
97% Sustained Virologic Response in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Receiving Sofosbuvir in Combination With Ribavirin for 12 Weeks: Results From a Phase 3 Multicenter Study
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Masao Omata,1 Shuhei Nishiguchi,2 Yoshiyuki Ueno,3 Hitoshi Mochizuki,1 Namiki Izumi,4 Fusao Ikeda,5 Hidenori Toyoda,6 Osamu Yokosuka,7 Kazushige Nirei,8 Takuya Genda,9 Takeji Umemura,10 Tetsuo Takehara,11 Naoya Sakamoto,12 Yoichi Nishigaki,13 Kunio Nakane,14
Nobuo Toda,15 Tatsuya Ide,16 Mikio Yanase,17 Keisuke Hino,18 Juan Betular,19 Bing Gao,19 Hongmei Mo,19 Akinobu Ishizaki,19 Masa Omote,19 Diana M. Brainard,19 Steven J. Knox,19 William T. Symonds,19 John G. McHutchison,19 Hiroshi Yatsuhashi,20 Masashi Mizokami17
1Yamanashi Prefectural Hospital Organization, Yamanashi, Japan; 2Hyogo College of Medicine, Hyogo, Japan; 3Yamagata University, Yamagata, Japan; 4Musashino Red Cross Hospital, Tokyo, Japan; 5Okayama University, Okayama, Japan; 6Ogaki Municipal Hospital, Gifu, Japan; 7Chiba University, Chiba, Japan; 8Nihon University, Tokyo, Japan; 9Juntendo University, Tokyo, Japan; 10Shinshu University, Nagano, Japan; 11Osaka University, Osaka, Japan; 12Hokkaido University, Hokkaido, Japan; 13Gifu Municipal Hospital, Gifu, Japan; 14Akita City Hospital, Akita, Japan;15Mitsui Memorial Hospital, Tokyo, Japan; 16Kurume University, Kurume, Japan; 17National Center for Global Health and Medicine, Tokyo, Japan; 18Kawasaki Medical School, Okayama, Japan; 19Gilead Sciences, Inc., Foster City, CA; 20National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan
|
| |
|
|
|
|
|
